Metrics to compare | S2BP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipS2BPPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −4.0x | −0.4x | |
PEG Ratio | 0.00 | 0.09 | 0.00 | |
Price/Book | 0.0x | 2.7x | 2.6x | |
Price / LTM Sales | 0.0x | 8.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 52.9% | 57.3% | |
Fair Value Upside | Unlock | 5.6% | 8.9% | Unlock |
Syn2bio S.A., a biotechnology company, engages in the research and commercialization of Cardiac Marker, a radiopharmaceutical for diagnostic testing of heart disease in the field of myocardial perfusion. The company’s flagship project is the cardiotracer project, a radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. Additionally, it operates The Centre for Research on New Compounds, a unit engaged in the search for new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product. Syn2bio S.A. was incorporated in 2025 and is based in Warsaw, Poland.